Monte Rosa Therapeutics is raising approximately $300 million through a public offering of common stock and pre-funded warrants. This financing aims to fuel the advancement of their novel molecular glue degrader (MGD) medicines, particularly in autoimmune diseases, oncology, and other areas. The capital infusion follows positive clinical data presentations, bolstering investor confidence and supporting the company’s proprietary QuEEN™ discovery engine.

Johnson & Johnson has partnered with the U.S. administration to lower drug prices and expand its domestic footprint. This agreement will provide millions of Americans with access to discounted pharmaceuticals and exempt these medicines from U.S. tariffs. The company is reinforcing its $55 billion U.S. investment, with plans for two new advanced manufacturing facilities for cell therapies and biologics, creating thousands of jobs and demonstrating a commitment to U.S.-based production and innovation.

Murphy Oil Corporation has priced a $500 million offering of 6.500% Senior Notes due 2034. Proceeds will be used to redeem outstanding 5.875% notes due 2027 and 6.375% notes due 2028, repay borrowings under its revolving credit facility, and cover transaction fees and general corporate purposes. This move aims to optimize the company’s capital structure, reduce refinancing risk, and enhance financial flexibility.

A presidential endorsement following a meeting with Intel’s CEO boosted the company’s shares. President Trump highlighted the U.S. government’s significant stake, acquired through the CHIPS Act, which has already yielded substantial returns. Intel, facing competition, recently launched advanced U.S.-made chips, showcasing domestic manufacturing capabilities. This government investment and strategic recalibration aim to strengthen U.S. technological sovereignty amid complex global supply chains.

NASA’s Crew-11 mission is returning to Earth earlier than planned due to an undisclosed medical situation involving a crew member. The astronaut’s condition is stable, but the medical emergency led to the postponement of a scheduled spacewalk and an adjusted return date from the International Space Station. This event emphasizes the challenges of long-duration spaceflight and the need for adaptable mission planning.

TrueBlue refutes EHS Management’s claims, highlighting its successful strategic execution and board refreshment. The company asserts its current plan is driving improved financial results and profitable growth, making external shareholder action unnecessary. TrueBlue has proactively engaged with EHS, informing them of board changes prior to their public announcement and selected new directors for their superior expertise. The company regrets EHS’s pursuit of a costly proxy contest amidst ongoing positive transformation.

Investors navigate mixed market signals as Nasdaq dips while Dow shows resilience. Jim Cramer advises caution, emphasizing transient early-year jitters. Cantor Fitzgerald upgrades Alphabet (GOOGL) to “buy” on its strong AI positioning, highlighting Gemini models. Texas Roadhouse (TXRH) rebounds but faces headwinds from rising beef prices, prompting earnings risk awareness. Other stocks like Constellation Brands and Ford were also mentioned.

Mike Lindell Media Corp. plans an expanded 2026 media presence with enhanced Washington D.C. coverage and significant upgrades to LindellTV and VOCL. The conservative alternative to mainstream media will feature dedicated reporting from the White House, Capitol Hill, and the Pentagon. New programming and a redesigned digital platform with a news aggregation system are being introduced. VOCL Studio and a live streaming feature will empower content creators and influencers, offering an uncensored broadcasting option. The company aims to provide “the truth and a voice like never before” to its audience.

Nvidia’s stock faces Wall Street skepticism despite positive developments, including China’s approval of H200 AI chip imports. The company’s CEO highlighted robust growth in “physical AI” and strong demand for new platforms, with the CFO indicating upward revisions to future sales guidance. While current shareholders may await further catalysts, the stock’s current valuation offers an attractive entry point for new investors, supported by strong earnings growth projections and favorable technical indicators.

Crown Holdings will release its Q4 and full-year 2025 results on February 4, 2026, followed by an investor call. Analysts will focus on the packaging giant’s performance across its markets, its response to inflation and supply chain issues, and its strategies for specialty packaging and sustainability initiatives. Crown Holdings’ outlook on innovation and its global expansion will also be key discussion points.